Page 11 - Demo

IMpassion130 patient disposition
Atezo + nab-P
902 randomised
Plac + nab-P
ITT population:
N = 451
PD-L1+ patients:
n = 185 (41%)
Death: n = 181 Loss to follow-up:
n = 24
Death: n = 208 Loss to follow-up:
n = 24
On study
n = 246
On study
n = 219
Survival follow-up
n = 182
On treatment
n = 64
(64 on A; 43 on nab-P)
⚫ Safety-evaluable population: 438a
Data cutoff: 17 April 2018. a 6 patients per arm did not receive study treatment; 7 patients in the Plac + nab-P arm received 1 dose of atezolizumab and were evaluated in the Atezo + nab-P safety population.
Schmid, et al. N Engl J Med 2018
⚫ Safety-evaluable population: 452a
Survival follow-up
n = 166
ITT population:
N = 451
PD-L1+ patients:
n = 184 (41%)
On treatment
n = 53
(53 on P; 35 on nab-P)